



THE CONTRIBUTIONS OF THE OMPF AND OSMB GENES IN 
PROMOTING YERSINIA PSEUDOTUBERCULOSIS SURVIVAL 









A thesis submitted to Johns Hopkins University in conformity with the requirements for the 


























© 2021 Robert Davidson 
All rights reserved 
  





Antibiotic-resistant bacterial infections pose a major public health threat. The current 
rise in antibiotic resistance is potentially leading to a post-antibiotic era in which antibiotics may 
no longer be useful in treating many bacterial infections.  Within bacterial populations there 
exist subpopulations of antibiotic-tolerant cells defined as persisters, or persistent cells, whose 
reduced metabolic activity and slowed growth rates reduce their susceptibility to antibiotics. 
Persisters are known to harbor and spread antibiotic resistance genes, which contribute to the 
threat of antibiotic resistance.  Exposure to antibiotics has been shown to promote persistence, 
however, few studies have characterized persister cell formation within host tissues.  
In this thesis, the role of clinically relevant doses of antibiotics in the induction of 
persistence is explored in Yersinia pseudotuberculosis. It is shown that Osmotically-inducible 
lipoprotein B(OsmB) and Outer membrane porin F (OmpF) play a role in the accumulation of 
antibiotics within bacterial cells.  Expression of these gene products, however, did not 
significantly impact the susceptibility of Y. pseudotuberculosis to doxycycline. 
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Antibiotic-resistant infection is an ever-growing threat to public health. There are 
approximately 2.8 million cases of antibiotic resistant infections in the United States each year 
according to the Centers for Disease Control and Prevention (1).  Antibiotic resistant infections 
are difficult to treat and not only lead to increased morbidity and mortality but also cost roughly 
$4.6 billion a year to treat (2). The World Health Organization has listed antimicrobial resistance 
as one of the top ten threats to global public health (3).  
There are several reasons bacterial infections may survive within a host following 
antibiotic treatment. The bacteria causing the infection may be resistant to the antibiotic being 
used to treat the infection (1, 4-7).  The bacterial population may be tolerant to antibiotics and 
regrow after treatment (7-12). The bacteria may be in sites such as deep tissues that are not 
easily accessible to antibiotics. Or lastly, subpopulations of bacteria within the infection may 
have reduced susceptibility to antibiotics (2, 13-15).   
Persistent bacteria, known as persisters, are a subpopulation of bacteria that are less 
susceptible to antibiotics and remain after antibiotic therapy. Persistent bacteria are known to 
cause recurrent infection and drive resistance (14).  Persistent bacteria have been called a 
catalyst for the increase of antibiotic resistance due to their ability to serve as a reservoir of 
antibiotic resistance genes that can be passed on to other bacteria (16).  The identification of 
potential therapeutic targets to eliminate persistent bacteria within an infection would allow for 
more effective treatment of these infections and reduce the rate at which antibiotic resistance 
is spreading.  
Persisters arise naturally during bacterial infection and can survive antibiotic treatment 
even when the majority of the bacteria in the population are susceptible to antibiotics (17).  




Persistence is most often the result of corrupted central metabolism, however there are diverse 
stressors that can lead to this phenotype (18, 19). To investigate the potential role of antibiotics 
as a stressor leading to persistence, a Yersinia pseudotuberculosis model was used. Doxycycline 
is an antibiotic commonly used to treat Yersinia infections in humans and animals, and in a 
mouse model of infection, Y. pseudotuberculosis is able to survive treatment with doxycycline 
(7). It is unclear what allows for this survival. Doxycycline accumulation may lead to adaptations 
by the bacteria that protect them from antibiotic treatment. When exposed to doses of 
doxycycline between 10ng/ml and 100ng/ml, the expression of outer membrane proteins OsmB, 
a lipoprotein, and OmpF, a porin, is increased (20, 21).   
To determine if the adaptation caused by doxycycline promotes antibiotic persistence 
during Y. pseudotuberculosis infection, deletion strains for the genes osmB and ompF were 
tested to measure their antibiotic susceptibility and accumulation in vitro. A Y. 
pseudotuberculosis mouse model of infection was also used to examine if osmB and ompF affect 
antibiotic susceptibility in vivo. 
 
Antibiotics 
Antibiotics can be broken down into two general categories: bactericidal, those 
antibiotics that directly kill bacteria; and bacteriostatic, those antibiotics that restrict bacterial 
growth. The activity of an antibiotic may change depending on the conditions in which it is used 
and the bacteria against which it is being targeted (22).  At sufficiently high concentrations some 
bacteriostatic antibiotics will cause cell death. It is not clear, however, how this happens in all 
cases.  
For any antibiotic to be effective it needs to be able to penetrate a cell through porins or 
by diffusion through the cell membrane. The antibiotic then needs to be able to bind to a 




cellular target to either kill the bacteria or arrest its growth. Bactericidal and bacteriostatic 
antibiotics target aspects of bacterial physiology that are unique from human cells such as the 
cell wall, protein synthesis, and nucleic acid synthesis (4).  
Bactericidal antibiotics such as β-lactams can directly kill bacteria by inhibiting cell wall 
synthesis. β-lactams bind penicillin-binding protein to prevent cross linking of N-
acetylglucosamine (NAG) and N-acetylmuramic acid (NAM), which compromises the integrity of 
peptidoglycan that makes up the bacterial cell wall (Figure 1.). Disruption of the cell wall can 
then lead to cell death. Death in this case results from lysis of the bacteria as the compromised 
cell wall is unable to withstand osmotic stress (22).  
Bacteriostatic antibiotics in general inhibit some aspect metabolism to prevent growth. 
Tetracyclines are a family of bacteriostatic antibiotics commonly used to treat both human and 
animal infections. Tetracyclines act by binding the 30S ribosomal subunit of the bacterial 
ribosome (Figure 1.). Bacterial ribosomes present an attractive target for antibiotics because 
they have significant differences from eukaryotic ribosomes. Binding of the 30S subunit by 
tetracyclines prevents charged tRNA from entering the ribosome and inhibits protein synthesis. 
The mechanisms that lead to clearance of an infection after treatment with bacteriostatic 
antibiotics remain a matter of debate. However, clearance may be mediated by the host 
immune response or cell death caused by the accumulation of toxic metabolites leading to DNA 
damage in the bacteria (22).  
Antibiotic Resistance  
Antibiotic resistance is caused by specific resistance genes or mutations that prevent the 
activity of an antibiotic and significantly increase the minimum inhibitory concentration (MIC) of 




antibiotic needed for activity.  The MIC is the minimum concentration of antibiotic at which 
bacteria are killed or cannot grow (4). 
Antibiotic resistance can be caused by multiple mechanisms such as antibiotic-degrading 
enzymes, efflux pumps, and alterations to the targets of antibiotics (Figure 1.).  The genes that 
encode these mechanisms can commonly be found on mobile genetic elements such as 
plasmids, transposons, and phages, which allow antibiotic-susceptible bacteria to rapidly 
acquire resistance genes (4, 17, 23, 24).  These genes are heritable, all daughter cells will have a 
resistant phenotype.  Antibiotic resistance genes may not be ubiquitous in a population at the 
initiation of an infection, however, treatment will select for this population and lead to the 
entire population being resistant.  
It has been demonstrated that genes that encode efflux pumps or antibiotic degrading 
enzymes were present in bacterial populations before the widespread use of antibiotics (25).  
This is because bacteria and other microorganisms produce antimicrobial compounds to out-
compete other bacteria or fungi.  To counteract such antimicrobial compounds, bacteria 
developed resistance mechanisms (26).  Many antibiotics in use today were first identified in 
microorganisms such as bacteria and fungi (22).  The increased use of human-derived antibiotics 
to treat bacterial infection and widespread antibiotic use in agriculture have created selective 
pressure leading to the rapid emergence and spread of antibiotic resistance (27). 
Common Antibiotic-Resistant Infections 
 Many antibiotic-resistant infections are acquired in hospitals (nosocomial infections) 
and can lead to prolonged stays and worsened outcomes for patients who are often already in 
poor health. Ventilator-associated pneumonia (VAP) and Clostridioides difficile infections are 
both dangerous infections that are acquired in a hospital setting. Antibiotic resistance is  







Figure 1. Antibiotic targets and resistance mechanisms. (Adapted from Wright, 2010) 
Common targets for antibiotics are identified on the left side of the image along with major families of antibiotics 
that use these targets. Antibiotic resistance strategies utilized by bacteria to escape killing by antibiotics are listed 
on the right along with families of antibiotics that are affected by these resistance mechanisms. 




frequently reported in bacterial VAP and C. difficile infections complicating the treatment for 
these infections. 
Ventilator-associated pneumonia (VAP), caused by multiple genera of bacteria such as 
Enterococcus and Staphylococcus, is the most common nosocomial infection acquired in 
intensive care units.  Enterococcus and Staphylococcus can be multi-drug resistant and the site 
of VAP being in the lungs can further limit antibiotic diffusion and make these infections difficult 
to clear. During the SARS-CoV-2 pandemic there has been a reported increase in VAP and 
worsened outcomes in patients with both COVID-19 and VAP (28).  In some settings the rates of 
drug resistance in VAP can range between 40-80%, making the treatment more difficult for 
patients who are already intubated (29).  
Clostridioides difficile is another dangerous antibiotic-resistant nosocomial infection. 
This infection is often caused by treatment with antibiotics for other infections and can arise 
from dysbiosis after the normal gut microbiome is altered by antibiotics (30). C. difficile is 
present in the gastrointestinal tract of many individuals, however, it is usually unable to out-
compete other members of the microbiome (31). When broad spectrum antibiotics are used to 
treat bacterial infections or during surgical procedures, large populations of bacteria in the 
intestinal microbiota are killed off allowing for the antibiotic resistant C. difficile to replicate to 
dangerous numbers, which can lead to debilitating diarrheal disease and recurrent intestinal 
infections.  
The threat of antibiotic resistance also extends outside of the hospital setting. Many 
pathogenic bacteria, such as Mycobacterium tuberculosis and Neisseria gonorrhea have 
acquired antibiotic resistance, and these infections are more commonly community acquired. 
M. tuberculosis infections require long-term treatment ranging from six months to years with 




multiple antibiotics such as rifampin, isoniazid, and fluoroquinolones (32).  This treatment has 
further been complicated with the emergence of multi-drug resistant and extensively drug 
resistant M. tuberculosis. Multi-drug resistant M. tuberculosis (MDR-TB) is resistant to rifampin 
and isoniazid, and extensively drug resistant M. tuberculosis (XDR-TB), which are MDR-TB strains 
that are resistant to fluoroquinolones and second line antibiotics (33).  The World Health 
Organization reported that in 2016, 240,00 people died from infections with MDR-TB and a 4.1 
per cent increase in cases. Rising rates of drug resistance in M. tuberculosis is a global threat 
that will continue to lead to more deaths (34). 
 
Antibiotic Persistence 
All bacterial populations are heterogeneous. One aspect of this heterogeneity is the 
presence of subpopulations of bacteria that stochastically arise that manifest reduced metabolic 
activity and slowed growth rates (35). These slow-growing cells are defined as persistent cells, or 
persisters (36). Reduced metabolism is strongly linked to persistence during antibiotic treatment 
(37).  Antibiotics do not act effectively on these cell populations, and persisters will remain 
following antibiotic treatment. It is thought that these persistent bacteria arise within the 
population at a set rate, with that rate varying greatly from species to species, and even from 
strain to strain within a species (35). The presence of persistent bacteria can prevent effective 
clearance of the infection and lead to recurrent infections. 
Research has shown that the presence of persistent cells in a bacterial infection can be a 
driver of the spread of antibiotic resistance.  Persisters can lead to antibiotic resistance through 
several mechanisms. The same pathways that can induce persister cell formation, such as the 
SOS response, can also lead to an increased rate of mutations, which can alter the target of 
antibiotics (38).  The SOS response is the bacterial response to DNA damage that has diverse 




effects on the cell many of which lead to tollerace. Persisters can also serve as a reservoir for 
mobile genetic elements that contain antibiotic resistance genes (39). The stressors that lead to 
persistence also cause the activation of these mobile genetic elements spreading antibiotic 
resistance genes to previously susceptible populations of bacteria.  
When an infection containing persistent bacteria is treated, the majority of the 
population will be killed off, leaving a persistent subpopulation that can regrow after treatment. 
Clearance of persistent bacteria is important to fully treat an infection and avoid recurrent 
infections.  The reduced activity of antibiotics against metabolically inactive persisters is 
generally thought to result from the reduced availability of antibiotic targets. Many antibiotics 
target bacterial processes such as protein synthesis and cell wall synthesis that are most active 
during growth. Reduced activity of these pathways can result in fewer targets for antibiotics. 
Antibiotics in the β-lactam family, for example, target cell wall synthesis, and without active 
synthesis they do not kill bacterial cells (40). Reduced metabolism may also limit the targets for 
other antibiotics. Lower ribosomal content in less active cells could potentially limit the efficacy 
of doxycycline and other tetracycline derivatives that target the ribosome (4).  
Persistent bacteria do not require antibiotic resistance genes to survive antibiotic 
treatment, but it is thought that there is a genetic basis for the switch to a persistent phenotype. 
Persistence is a phenotypic change that can be induced by reduced metabolism and dormancy. 
Dormancy is a state of non-division that allows bacteria to survive harsh environments. The 
signaling that initiates phenotypic switch to slowed metabolism or dormancy is genetically 
encoded.  This has been shown through the enrichment of persister bacteria within a population 
after multiple brief rounds of antibiotic treatment (16).  Altering the rates of persister formation 
is thought to allow bacterial populations to respond to changes in their environment by 
increasing the rate of persister formation in harsh conditions or reducing the rate of persister 




formation in more hospitable conditions. The occurrence of persisters in bacterial populations 
has been proposed to be a bet-hedging strategy where the bacterial population sacrifices some 
potential for growth to be able to survive harsh conditions such as low pH, desiccation, and 
exposure to antibiotics. There are also other theories that explain persistence as arising from 
random cellular errors that lead to growth arrest. The genetic foundation of bacterial 
persistence is not yet well understood (41). There are currently very few drugs that directly 
target persistent infections, which are generally treated with short treatments of high doses of 
antibiotics or long treatments with low antibiotic doses. High-dose interval treatment has been 
shown in vitro to increase the percentage of the population that is persistent, making these 
infections particularly difficult to treat (16). 
It is difficult to directly measure the impact of persistence. Detecting persistent cells 
once the bacteria is cultured from a patient is difficult because the bacteria are no longer 
exposed to the stressors that led to persistence in the host. These infections may not be 
culturable because they are metabolically inactive or dormant, further complicating diagnosis. 
Measuring antibiotic persistence is more complicated than measuring antibiotic resistance, 
which can be directly measured at the population level by calculating the MIC and is not 
dependent on a stress induced phenotype. The reversal of the persistent phenotypes when 
removed from stressors and the potential to be nonculturable make the rapid diagnosis and 
surveillance of the presence of persistent cells more complicated than surveillance of resistance.  
The complicated nature of surveillance of persistent infections makes it difficult to fully assess 
the impact of persistent infections, and can led to the misidentification of persistent infections 
as resistant infections (14).   




Common Antibiotic-Persistent Infections 
There are many common bacteria that can establish persistent infections including M. 
tuberculosis, Salmonella typhi, S. aureus, ureopathogentic Escherichia coli (UPEC), and 
Pseudomonas aeruginosa in patients with cystic fibrosis. The most prevalent example of a 
bacterial pathogen that establishes persistent subpopulations is M. tuberculosis. M. tuberculosis 
infections are also the most prevalent bacterial infection worldwide, with roughly one third of 
the world’s population latently infected with M. tuberculosis (34).  During infections with M. 
tuberculosis, bacteria invade alveolar macrophages and are sequestered into granuloma 
structures as other immune cells infiltrate the area to contain the infection with the infected 
macrophages at the center of the granuloma. Within these infections there is frequently a 
subset of persister bacteria. M. tuberculosis replicates very slowly, (even under ideal laboratory 
conditions), which may also add to the high degree of persistence seen in these infections (19, 
42).  
Persistence within a M. tuberculosis infection is caused by several factors. Slowed 
growth and metabolism, which are two of the most well-supported causes of antibiotic 
persistence, greatly limit the effectiveness of antibiotic treatment in M. tuberculosis infections.  
The subpopulations of persistent bacteria within a M. tuberculosis infection greatly contribute to 
the length of treatment required to eradicate M. tuberculosis from patients. Antibiotic 
treatment can last nine months and must be treated with a combination of antibiotics including 
rifampin, isoniazid, and fluoroquinolones. Long courses of antibiotics, such as those required for 
the treatment of M. tuberculosis, increase the total volume of antibiotics in the environment 
(33). This is another avenue by which persistent bacteria can indirectly contribute to antibiotic 
resistance, by increasing the total amount of antibiotic required to treat infections. Prolonged 
exposure to antibiotics during treatment, and failure of patients to comply with a long and 




expensive treatment, can also lead to resistance within the population of the bacterial infection, 
which has led to the emergence of MDR-TB and XDR-TB.  
Other common bacterial pathogens, such as S. typhi and S. aureus, spread systemically 
to establish infection in deep tissues such as the liver and spleen, and are additional examples of 
common, persistent bacterial infections (9, 39). Deep tissue infections can arise after systemic 
infection, when bacteria spread from one tissue into the bloodstream, and then seed other 
tissues. These infections, like all other tolerant or persistent infections, can then lead to 
recurrent infections after completion of treatment for a systemic infection because bacteria 
may remain within deep tissues (43).  In deep tissue sites, antibiotics may not accumulate to 
levels required to completely clear the infection.  In some cases, interactions with the host or 
other bacteria in deep tissue sites can lead to the development of a persistent population of 
bacteria in the infection, which further complicates treatment. For example S. typhi has been 
shown to enter a persistent state after macrophage engulfment while growing within an 
intracellular salmonella-containing vacuole (44).   
Repeated treatments for recurrent infections negatively impact patients who suffer 
from these infections, both physically and financially, and can lead to more severe infections if 
left untreated (45). Uropathogenic E. coli (UPEC) is one of the most well-studied bacteria that 
establishes persistent infections. The mechanisms of persistence used by UPEC, discussed 
below, are significantly different from those that lead to persistence in deep tissue and 
Salmonella infections (36). These infections, unlike deep tissue infections, do not arise from 
systemic infections, but rather from local infections leading to urinary tract infections (46). 
Studying this system can shed light on treatment for urinary tract infections that are one of the 
most common bacterial infections in women.  Individuals with recurrent urinary tract infections 




require multiple, frequent rounds of antibiotic treatment and, if left untreated, these infection 
can lead to more dangerous kidney infections (46).   
Causes of Persistence 
While there are many well-established mechanisms of antibiotic resistance, the causes 
of persistence remain less clear and need to be further elucidated in order to develop 
therapeutics that directly target persistent bacteria. Antibiotic persistence has been more 
difficult to study because the conditions that cause persistence can be difficult to recreate in 
vitro.  Studying antibiotic persistence is further complicated because persistence may not be 
specific to a single antibiotic. Dormancy or slowed metabolism within a population can lead to 
multidrug persistence.  Dormancy or quiescence is a state of non-division that can be entered by 
many environmental bacteria and M. tuberculosis. Dormancy allows bacteria to survive in 
inhospitable environments such as starvation conditions. Because of this broad protective effect 
provided by dormancy, it can be triggered by multiple redundant pathways (47). There are also 
multiple stress response pathways that can slow growth and metabolism while not entirely 
arresting growth, leading to persistence during infections. These pathways can be dependent on 
both host and bacterial factors and are initiated by multiple different environmental stressors.  
Recent advances, such as RNA sequencing and other genomic and proteomic approaches, have 
allowed researchers to learn more about these pathways. 
The events that induce persistence are varied and range from exposure to reactive 
oxygen species (ROS) and signals from other bacteria within the environment, to direct 
responses to the antibiotic itself (Figure 2) (15, 16, 48, 49).  Some common pathways that lead 
to persistence are the SOS response along with the secondary signal tetraphosphate or 
pentaphosphate guanosine (pppGpp or ppGpp), activation of toxin-antitoxin systems, and  





Figure 2. Extracellular signals that cause antibiotic persistence. (Adapted from Gollan et al., 2019) 
Extracellular signal of antibiotic persistence are circled in red. Known stress response pathways triggered by these 
signals are in blue and green and known effectors of these pathways are shown in orange. 
  




responses to oxidative stress (17, 26, 40). Many of these pathways can lead to reduced 
metabolism, which is currently thought to be the strongest driver of persistence (37). However, 
slowed metabolism is not the only cause of persistence. Other mechanisms include inducing 
efflux pump expression or the expression of an antioxidative response (19, 50). Antioxidative 
proteins can prevent killing through the accumulation of ROS which is thought to be key way 
that antibiotics cause bacterial cell death. It is important to note that there is a set rate of 
persister formation even in ideal conditions and there is always a subpopulation of persistent 
cells in the population. The subpopulation of persisters can expand when the entire population 
experiences stressors. Stressors such as limited access to nutrients and interactions with the 
immune system within the host environment can induce the SOS response or toxin-antitoxin 
systems and induce persistence (38, 51).   
Nutrient Limitation 
It has recently been demonstrated that when uncoupled with growth, metabolism is a 
better indicator of antibiotic susceptibility to bactericidal antibiotics (37). This may have to do 
with the reduced availability of antibiotic targets during slowed growth. Many antibiotics 
require cellular activity for efficacy. β-lactams that target the cell wall, for example, require 
active cell wall synthesis to kill bacteria. Other antibiotics that target protein synthesis, such as 
tetracyclines that bind the 30S ribosomal subunit, may not be effective if the bacteria are 
dormant and not translating protein.  
Starvation, or nutrient limitation, was one of the earliest described inducers of 
persistence in bacterial infections, and slowed metabolic rates remain one of the most well-
studied inducers of persistence (37). While many factors can lead to persister cell formation as a 
result of starvation, it is most often linked to the SOS response and (p)ppGpp accumulation. In E. 




coli the SOS response is initiated by RecA being recruited to single-stranded DNA. This leads to 
the auto-proteolysis of LexA which allows for the expression of genes that are repressed by 
LexA. The SOS response has global and varying effects on cells including dormancy caused by 
activation of the TisB toxin-antitoxin module.  Starvation can also induce an SOS response in 
which bacteria produce (p)ppGpp signaling a transcriptional switch to a dormant phenotype 
(38). Similarly, when bacteria reach stationary phase, the point in growth when division stops, 
they become much more tolerant to antibiotics. This is also due in part to slowed growth and an 
accumulation of (p)ppGpp (52). 
The accumulation of (p)ppGpp in bacterial cells and the SOS response can also promote 
biofilm formation, which can impact antibiotic efficacy. Biofilms are well known to cause 
persistent infections associated with medically indwelling devices, and biofilms can promote 
severe infections in cystic fibrosis patients who are colonized with Pseudomonas aeruginosa 
(15). While it was long thought that persistence in biofilms was due to an inability of antibiotics 
to reach a high concentration in the center of the biofilm colony structure, it has recently been 
demonstrated that some antibiotics can penetrate biofilms (18, 53). This indicates that the high 
level of persisters that are present in biofilms are probably playing a more significant role in the 
recalcitrance of biofilms, compared to the ability of antibiotics to accumulate within biofilms 
(18). Nutritional stress can occur during infection when a population of bacteria has either used 
the local nutrients that are required for growth or as a result of sequestration of nutrients such 
as iron. Interactions with the host immune system can also arrest growth. 
Toxin-Antitoxin Systems 
Toxin-antitoxin (TA) pathways are another major group of signaling pathways that can 
induce persistence through arresting growth. TA systems encode a toxin that is harmful to the 




bacteria along with the antitoxin that prevents its activity. In ideal conditions the ratio of toxin 
to antioxin is 1:1 to prevent toxin activity. When the balance of toxin to antitoxin favors the 
toxin, the toxin is no longer effectively neutralized and can affect it’s cellular targets. Toxins can 
have a wide range of effects include inducing biofilm formation, disrupting proton motive force, 
and inhibiting transcription and translation (24). Proton motive force is the proton gradient 
established in the bacterial cell membrane that is used for ATP synthesis (54).  
There are two types of TA systems, type I and type II, that have been studied in the 
context of persistence. Type I TA antitoxins are antisense RNAs that prevent expression of their 
conjugate toxin by binding mRNA transcripts and inhibiting translation (10). Type I toxins are 
generally small pore forming toxins that insert into the bacterial membrane and disrupt ATP 
synthesis by altering the proton motive force (10).  The ability of type I TA modules to induce 
persistence has been well characterized in the K12 lab strain of E. coli. Type II antitoxins are 
proteins that directly act on their toxin protein to inactive them.  The functions of these proteins 
are much more diverse; however, many inhibit translation by acting on mRNAs, tRNAs or even 
rRNAs.  
Type I and II TAs can also be activated by the SOS response and in response to (p)ppGpp 
accumulation.  The activity of these systems may not completely inhibit bacterial growth, but it 
can drastically reduce the growth rate and metabolic activity of bacterial cells, and lead to an 
increased number of persister cells within the population. The study of these pathways, like the 
study of the other causes of persister formation, is complicated by the considerable redundancy 
that has been observed in these pathways in E. coli.   
Induction of persistence and chronic infection by TA modules have also been studied in 
S. aureus.  The MazEF TA module in S. aureus has been implicated in regulating biofilm 




production and antibiotic persistence in vitro and in a murine model of infection (24). The toxin 
MazF is an endoribonuclease that cleaves single stranded ACA sequences in mRNA to inhibit 
translation (24). MazF has been shown to drive tolerance in biofilms in many Gram-negative 
bacteria, and as expected MazF deficient mutants show increased susceptibility to antibiotics 
within biofilm communities. It was also demonstrated that loss of the mazF toxin leads to 
increased biofilm production. This was not an expected result. Further investigation revealed 
that biofilm formation was dependent on the ica operon and the expression of the 
polysaccharide intracellular adhesin (PIA). PIA helps in regulation of biofilm production and 
increased levels of the adhesin in the absence of MazF indicate a regulatory role of MazF in the 
expression of PIA. This result is interesting as biofilm production is often corelated with 
antibiotic persistence and this demonstrates that he biofilm in isolation may not be completely 
protective (24).  
Immune Interactions 
The host immune system is thought to induce persistence in multiple ways. The innate 
immune response initially controls many bacterial infections through interactions with 
neutrophils or macrophages. These innate cells utilize mechanisms such as phagocytosis and the 
production of reactive oxygen species (ROS) and secreted reactive nitrogen species (RNS) to 
contain and eliminate bacteria (23, 50).  The same responses that are effective at controlling the 
spread of bacteria also inhibit growth or stress bacterial cells and can lead to antibiotic 
persistence (50). One area with a significant body of research in this area is the role of ROS in 
the induction of persistence.  There are several well-described pathways down stream of ROS 
exposure that can lead to tolerance such as the induction of the SOS response and the 
mobilization of an antioxidative response to mitigate antibiotic killing through the production of 
ROS. Stressors experienced in the phagosome following phagocytosis, which include exposure to 




ROS among conditions such as a low pH, have also been shown to induce persistence. Other 
immune interactions such as exposure to RNS have been shown to induce tolerance in some 
systems, however this area remains poorly understood. 
There are several proposed mechanisms through which interactions with RNS and ROS 
lead to persistence, and these mechanisms may be species and antibiotic specific. In some 
species such as Streptococcus mutans, it appears interaction with host-derived ROS promotes 
the expression of antioxidant defenses and prevents killing by antibiotics that kill through the 
production of ROS (50). This, however, does not hold true for other systems, in which it appears 
that corruption of central metabolism or breakdown of proton motive force increases the rate 
of metabolically inactive persisters (17). A third, less common, mechanism by which immune 
cells can cause tolerance is the induction of efflux pumps. The induction of efflux pumps is not 
dependent on the presence of ROS or RNS. The engulfment into macrophages promotes the 
expression of the Rv1258c efflux pump in M. tuberculosis., which confers rifampin tolerance. 
This interaction has been shown in multiple M. tuberculosis group clinical isolates (19). 
Oxidative and Nitrosative Stress 
The role of ROS in antibiotic killing of bacteria is currently a debated field because 
oxidative stress can induce persistence as well as lead to bacterial cell death. ROS have been 
shown to induce persistence in M. tuberculosis, E. coli, S. mutans, and S. aureus (50, 55). The 
induction of persistence through ROS stress is of particular importance during infection. 
Macrophages eliminate bacteria after phagocytosis with oxidative bursts. Bacteria that are able 
to survive this interaction may become persistent. 
S. mutans is a bacterium that is part of the normal oral microflora. This bacterium can 
cause biofilm formation in the mouth, leading to cavities, as well as cause infective endocarditis 




and bacteriemia when it is introduced into the bloodstream. Oral bacteria can be introduced 
into the bloodstream during dental surgery and even while brushing teeth. During extra-oral 
infections, S. mutans will also form biofilms, and can be difficult to treat due to antibiotic 
persistence that is commonly observed in biofilm communities. Persistence in S. mutans biofilms 
has been directly linked to oxidative stress. When the transcriptional regulator SpxA1, which 
regulates the expression of genes related to oxidative stress, was knocked out, S. mutans, 
bacteria within biofilms were significantly more susceptible to gentamicin, vancomycin, and 
linezolid.  This demonstrates that the ability to rapidly respond to oxidative stress can have a 
protective effect against many bactericidal antibiotics, which may cause death through 
generating oxidative stress (50). ROS produced by the immune system can also lead to 
persistence by altering bacterial metabolism (17). 
The impact of altered metabolism caused by ROS on the induction of persistence has 
been studied in S. aureus. S. aureus is a common pathogenic bacterium that causes a wide array 
of infections in humans. Many of the more serious infections, such as sepsis, are a result of 
bloodstream infections that can be initiated by skin infections. When bloodstream access results 
in colonization of blood-rich organs, these infections are referred to as deep tissue infections. 
Deep tissue infections can be difficult to clear with antibiotic treatment, even in strains of S. 
aureus that are susceptible to antibiotics due to their limited diffusion in deep tissues. S. aureus 
infections are primarily controlled through phagocytosis by neutrophils and macrophages; 
however, phagocytosis by macrophages can lead to persistence though the generation of ROS. 
S. aureus can also avoid killing by macrophages, which can lead to the establishment of a 
reservoir for reinfection within macrophages. Macrophages kill phagocytosed bacteria through 
the oxidative burst. It has recently been demonstrated that the oxidative burst, while killing the 
majority of bacteria, can also lead to multidrug persistence in the surviving bacteria. This was 




shown by infecting macrophages that were activated by exposure to LPS and IFNγ with S. 
aureus, which led to intracellular ROS exposure. These macrophages were then treated with 
rifampin to determine if the intracellular bacteria were killed. It was proposed that the 
inactivation of the enzymes aconitase and succinate dehydrogenase in S. aureus, caused by 
interactions between ROS and Fe-S clusters in the enzymes, led to disruptions in the central 
metabolism of S. aureus and persistence (55). Because ROS are an important component in the 
immune response to bacterial infections, it is difficult to develop and use drugs that inhibit these 
pathways and target persistent bacteria. Recovering metabolic pathways inhibited by ROS or 
targeting enzymes that inhibit killing by ROS present more attractive future antimicrobial 
compound targets.  
In addition to ROS, the host immune system can also induce persistence in other ways. 
IFNγ-primed macrophages have also been shown to induce persistence to beta-lactams through 
the production of RNS in Burkholderia pseudomallei and nontyphoidal Salmonella. In this 
system, it was shown that the collapse of PMF and inhibition of central metabolism plays a 
stronger role than mounting an antioxidative defense in the development of persistence in this 
system.  This may indicate that the persistence observed here is a product of inducing persisters 
by interfering with metabolism in these populations (23).  
RNS have also been found to promote persistence in a Y. pseudotuberculosis model of 
infection.  During an infection with Y. pseudotuberculosis, nitrosative stress from macrophages 
and monocytes is thought to be important in controlling the early stages of infection. As with 
many pathogenic bacteria, Y. pseudotuberculosis expresses nitric-oxide-reducing enzymes in 
response to stress from RNS to protect the bacterial population from these antimicrobials.  
Heterogeneous expression of the nitric-oxide-reducing gene, hmp, has previously been 
described in Y. pseudotuberculosis spleen infections, where a subpopulation of bacteria at the 




periphery of pyogranulomas responds to the RNS-derived stress and produces hmp. These hmp-
expressing bacteria preferentially survive treatment with doxycycline, implying that the 
nitrosative stress is inducing antibiotic persistence in the exposed population. Only about half of 
the surviving bacteria are from the hmp-expressing population however, indicating that there 
may be other factors contributing to persistence in this system. (7)  
Internalization of Salmonella typhimurium by macrophages has also been shown to 
induce persistence to cefotaxime, a 3rd generation cephalosporin, in vitro. Interestingly, the 
persistent non-dividing subpopulation maintains SPI-2 type-III secretion system activity to avoid 
killing within the macrophage. Cephalosporins target cell wall synthesis so in this model growth 
of the cells is necessary for the antibiotics to kill bacteria, so it may not hold true with other 
classes of antibiotics. (44) 
Antibiotic Stress 
Antibiotic stress can lead to persistence by inducing dormancy. The stress from 
daptomycin has been shown to induce multidrug persistence in S. aureus (8). Bactericidal 
antibiotics such as ciprofloxacin were used to induce a persistent phenotype that was not 
metabolically active in experiments to establish that activity of the SPI-2 type three secretion 
system is necessary for persistent S. typhimurium to survive in macrophages. S. typhimurium 
treated with ciprofloxacin were persistent with treated with other antibiotic however they were 
eliminated by activated macrophages (44). 
Antibiotic stress can also lead to persistence by promoting invasion of host cells. 
Intracellular bacteria are generally more protected from antibiotics than extracellular bacteria 
because many common antibiotics fail to adequately penetrate human cells and reach inhibitory 
levels. UPEC is known to establish biofilm-like communities in the bladder epithelial cells. It is 




thought that these are a contributing factor to recurrent UTIs as well as persistence that is 
commonly observed in UPEC. Sub-lethal doses of antibiotics can drive normally extracellular 
bacteria Bacillus cereus and S. aureus to invade host cells by inducing toxin expression that 
promotes invasion. B. cereus is not a major cause of human disease; however, it is known to 
cause food poisoning. Low doses of antibiotics were shown to induce non-hemolytic enterotoxin 
(Nhe) production in B. cereus and α-toxin expression in S. aureus.  The production of toxins by 
each of these species was also shown to promote invasion into IEC-6 cells, an intestinal 
epithelium cell line. In this model the antibiotics play a dual role in both prompting invasion and 
inhibiting essential cellular processes such as autophagy, to prevent the clearance of 
intracellular bacteria (56).  
Inhibitory doses of antibiotics have also been shown to enrich persister formation after 
high-dose, extended-interval therapy that is required when using more toxic antibiotics to clear 
infections that are resistant to other options. This method of therapy is common when treating 
the nosocomial “ESKAPE” bugs (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.), which 
are often multidrug resistant. After treating this group of bacteria with repeat high doses of 
aminoglycosides there was between a 37- and 213-fold increase in the formation of persister 
cells from evolved clones relative to the pretreatment rates of persister formation. (16) 
Yersinia pseudotuberculosis Model  
Yersinia pseudotuberculosis is a gram-negative enteric pathogen that can infect the 
intestinal epithelium and cause disseminated infection by accessing the lymphatic system. It is 
also the most recent common ancestor of Y. pestis, the causative agent of bubonic, septicemic 
and pneumonic plague. In an intestinal infection, which is its natural route of infection, Y. 
pseudotuberculosis invades M cells within the intestinal epithelium and utilizes these to cross  





Figure 3. Y.  pseudotuberculosis microcolony model. Y. pseudotuberculosis forms microcolonies surrounded by 
immune cells. In direct contact with Y. pseudotuberculosis are neutrophils that are in an inactive state due to the 
activity of the Y. pseudotuberculosis type III secretion system. Directly surrounding the layer of neutrophils is a layer 
of monocytes. 
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the intestinal barrier.  Y. pseudotuberculosis can then colonize Peyer’s patches (aggregates of 
lymphatic tissue in the intestinal ileum that survey the intestinal microbiota) and mesenteric 
lymph nodes.  Based on studies in mouse models of infection, subsets of bacteria remain within 
the intestinal lumen, and have been shown to directly access the bloodstream to cause 
systemic, disseminated infection (57). During systemic infection, Y. pseudotuberculosis will infect 
blood-rich organs, such as the liver and spleen, causing infection of these deep tissues. In deep 
tissue infections, Y. pseudotuberculosis establishes clonal, extracellular microcolonies that allow 
for the study of heterogeneous gene expression, and specifically expression of genes that 
promote infection, or virulence factors (58).   
Like all other pathogenic Yersinia species, Y. pseudotuberculosis has several mechanisms 
to evade the host immune response, such as expression of a type III secretion system (T3SS) that 
injects Yop (Yersinia outer proteins) effectors into host immune cells. Y. pseudotuberculosis 
typically utilizes the T3SS to target neutrophils and prevent activation and phagocytosis (57). 
Neutrophils and monocytes play an essential role in the containment of Y. pseudotuberculosis 
infections at early stages, before the infected individual succumbs to the infection. In 
immunocompromised individuals that cannot adequately contain the infection in the intestinal 
epithelium Y. pseudotuberculosis will cause disseminated infections and establish colonies in 
lymphatic tissues. The mouse model of infection more accurately recapitulates infection in 
immunocompromised individuals as Y. pseudotuberculosis can escape the intestine and mice will 
succumb to the infection.   
 In tissue infections, Yersinia forms microcolonies or pyogranulomas with a distinct 
architecture protected by a layer of neutrophiles that are unable to carry out phagocytoses due 
to the activity of the T3SS (Figure. 3).  Surrounding the layer or neutrophils is a population of 
monocytes that are not in contact with the bacteria but are able to interact with the bacteria 




through secreted factors such as RNS that diffuse into the microcolony (58). In response to these 
stressors, Y. pseudotuberculosis forms distinct bacterial subpopulations responding to the 
different types and amounts of host-derived stress. The structure of the microcolonies also 
effects diffusion of antibiotics such as doxycycline into the microcolony. It has been 
demonstrated by our lab that doxycycline accumulates to different levels in the periphery and 
the center of the microcolonies, accumulating to between 100ng/ml and 1μg/ml in the 
periphery and around 10ng/ml in the centroid. The diverse stressors experienced by different 
bacteria and clonal nature of these microcolonies makes them a useful tool to study the 
multiple causes of persistence, including host-derived stressors and exposure to antibiotics (7). 
Mouse Model of Y. pseudotuberculosis Infection 
To study the effects of these stressors in vivo, our laboratory utilizes a mouse model of 
infection. Several routes of infection are used in mouse models to study host-microbe 
interactions in the deep tissue stage of Y. pseudotuberculosis infection: an intravenous infection, 
infection through feeding, intraperitoneal injection (IP) and oral gavage. Each route of infection 
offers advantages and disadvantages. The intravenous route of infection utilized in this thesis 
allows for a more controlled load of bacteria to be administered, in contrast with other models 
commonly used to study Yersinia infections in vivo.  Directly introducing the bacterium into the 
bloodstream also ensures a consistent time frame for the infection and ensures that the 
infection will spread systemically and establish an infection in lymphoid organs such as the 
spleen. Oral infections, through either gavage or feeding, may not deliver a consistent inoculum 
to the spleen or other organs to set up a deep tissue infection. When mice are orally infected 
with Y. pseudotuberculosis, they pass bacteria in their stool and can become reinfected, or 
ingest a higher number of bacteria, than the experiment intended. In addition, gavage can cause 
damage to the throat which may affect disease progression. The oral routes of infection more 




closely mimic natural routes of infection. Due to the higher degree of variability with these 
models, however, we chose to use an intravenous route of infection. In an intraperitoneal (IP) 
infection model, it is not clear where or how the bacteria access the interior of organs and the 
bacterial load is less controlled. Tail vein infection more closely approximates the downstream 
bloodstream access that occurs during natural infection than IP and allows for a more controlled 
number of bacteria to be delivered directly to the spleen.  Y. pseudotuberculosis is an excellent 
model to study the effects of antibiotics in vivo because of the genetic tools that are available to 
modify it and the ease with which its genome is modified. In addition, the genome has been 
annotated, making genomic work more accessible.   
Adaptation Response to Doxycycline 
Doxycycline is commonly used to treat Yersinia infections in humans.  In the mouse 
model of infection, Y. pseudotuberculosis is able to survive one treatment with an inhibitory 
dose of doxycycline. It is not known what allows Y. pseudotuberculosis to survive treatment. The 
diverse stressors that are experienced by Y. pseudotuberculosis may lead to persistence that 
allow for the observed survival. The concentrations to which doxycycline accumulate within a 
microcolony may lead to adaptations by the bacteria that allow them to survive antibiotic 
treatment.   
To determine if there is an adaptation in response to doxycycline, RNA-seq was 
performed on populations of Y. pseudotuberculosis that had been exposed to a concentration of 
100ng/mL of doxycycline. Samples were taken at 2 hours and 4 hours for RNA isolation (Figure 
4.). From this experiment four genes with at least a two-fold change and significantly differential 
expression when compared to an untreated sample were identified at the two hour time point 
only.  By the fourth hour the difference was no longer significant. Two of these genes, osmB and 
ompF, showed increased expression in response to doxycycline, and two genes, tusB and CNFy, 




showed reduced expression.  It was then necessary to determine if the altered transcription 
levels of these genes effect antibiotic susceptibility of Y. pseudotuberculosis and, potentially, 
how the gene products are providing protection.   
Experimental Approach 
To determine if the adaptation to subinhibitory doses of antibiotics can promote 
antibiotic persistence during Y. pseudotuberculosis infection, deletion strains for the 
upregulated genes osmB and ompF were tested to measure their antibiotic susceptibility and 
accumulation. OmpF is an outer membrane porin that is upregulated in response to osmotic 
stress (21). In many studies with E. coli, porin-deficient mutants have been found to be more 
tolerant than wild type bacteria, so it is particularly interesting that increased expression of this 
protein was associated with exposure to antibiotics (59). OsmB is an outer membrane 
lipoprotein about which little is known. It has been observed that the presence of OsmB in the 
outer membrane allows for rapid remodeling of the outer membrane following osmotic stress, 
but it is unclear how this would aid in response to a bacteriostatic antibiotic such as doxycycline 
(20). Based on the location of both of these proteins in the outer membrane, we hypothesized 
that they may be affecting the accumulation of antibiotics within the cell. This may be mediated 
by allowing passive diffusion out of the cell through OmpF or by OsmB altering the composition 
of the membrane to inhibit diffusion into the cell. We expected to observe higher susceptibility 
in the knockout strains if these genes played an important role in the development of 
persistence. Accumulation of antibiotics was measured within individual and dual knockouts to 
determine if there was a difference in accumulation of antibiotics we predicted in these 
mutants. 
  





Bacterial Strains and Culture Conditions 
The mutant ΔosmB, ΔompF, and ΔosmB ΔompF strains of Y. pseudotuberculosis were 
derived from the IP2666 strain a clinical isolate first identified in France (60, 61). Overlap 
extension PCR was used to generate a fragment with 1kb up- and downstream regions fused 
together, lacking the gene of interest.  This was ligated into a suicide vector, introduced into 
IP2666 by conjugation, and homologous recombination was used to incorporate the deletion 
construct into the chromosome.  Insertion of the deletion construct was confirmed by PCR(62). 
IP2666 and all derived strains were grown in Miller’s Luria-Bertani (LB) medium, on LB agar, or in 
2xYT broth for plasmid purifications and infections. 2xYT broth contains twice the yeast extract 
and tryptone as Miller’s LB. To maintain reporters on plasmids the media and agar plates were 
supplemented with 25µg/ml of chloramphenicol (Cm), 100µg/ml of carbenicillin (Carb), or both 
antibiotics in some cases. Broth cultures and LB agar plates of all strains were grown at 26°C, to 
avoid the virulence factor expression in Y. pseudotuberculosis. Growth at 37°C induces 
expression of many virulence factors in Y. pseudotuberculosis (63-65). Y. pseudotuberculosis 
cultured LB agar plates were grown for 2 days. Broth cultures were grown with rotation to 
ensure aeration of the culture and to promote robust growth. For in vitro experiments all strains 
were grown at 37°C to induce virulence factor expression and more accurately model conditions 
experienced in infection.  
Plasmid Preparation and Purification 
Previously described reporters for tetracycline were used to construct reporter strains 
for ΔosmB, ΔompF, and ΔosmB ΔompF mutants. To isolate fresh plasmids for the 
transformations the Promega PureYield Plasmid Midiprep System (Promega Corporation, 
Madison, WI, USA, cat no A2492) was used. To perform the plasmid purification 50ml 2xYT 




broth cultures of the E. coli strain containing the plasmid of interest are grown overnight at 37°C 
with shaking. Following the overnight growth, the cultures must be transferred to a sterile 50 
conical tube and pelleted at 5000xg for 10m.  Following the pelleting step, the cells are 
resuspended in 3ml of resuspension solution using a serological pipette. When the cells are 
completely resuspended 3ml of lysis solution were added to the mixture. The 50ml conical tubes 
were rotated by hand to mix the lysis solution until the mixture became snotty. Upon complete 
lysis of the cells, 5ml of neutralization solution were added to the mixture and inverted to mix. 
The addition of the neutralization solution should cause the formation of a white precipitate. 
The lysate was then centrifuged at 4000 rpm for 15 m to pellet the precipitate out of solution. 
The supernatant was then carefully poured into the clearing column included with the kit 
stacked on top of the binding column in a vacuum manifold and the vacuum was applied to pass 
the supernatant through both columns. Following the initial use of the clearing column it was 
removed. To remove any LPS contaminants, 5ml of endotoxin removal solution was added to 
the column and pulled through with the vacuum. A final wash of 20ml of column wash solution 
was added and pulled through the column with the vacuum before the plasmid was eluted in 
600μl of dH2O. 
Transformation of Y. pseudotuberculosis to Introduce the Tetracycline Reporter 
To measure antibiotic accumulation within the ΔosmB, ΔompF, and ΔosmB ΔompF 
strains, a reporter based on the tetracycline resistance operon (Tre) was introduced into the 
deletions by transformation using electroporation (66). To transform Y. pseudotuberculosis, the 
strain of interest must first be grown overnight for 16 to 18 hours in LB broth with the 
appropriate antibiotics. After 16 to 18 hours growth the broth culture is diluted 1:50 into fresh 
LB and grown for two and a half to three hours to move the cells into the log phase of growth 
for electroporation. Following the incubation period, 1mL of cells from the dilution are pelleted 




for 1m at 15,000rpms at 4°C in a sterile microcentrifuge tube. The pelleted cells are put 
immediately on ice after removal from the microcentrifuge and the supernatant is then pipetted 
off. The cells are then resuspended in 1mL of ice-cold dH2O. The pelleting and resuspension 
steps are repeated 2 more times. The cells are then pelleted once more using the same 
conditions and resuspended in 50μL of ice-cold dH2O.  2μl of the plasmid pMMB67EH containing 
the PtetA::mCherry reporter at a concentration of roughly 150ng/μl were added to the 
resuspended cells on ice. The plasmid cell mixture was then added to a pre-chilled 2mm cuvette 
for electroporation. The cells were electroporated using a pulse at 2.2 kV for 4.6 to 4.8ms. 
Immediately following electroporation, 950μl of LB are added to the cuvette. The cells are then 
transferred to a sterile microcentrifuge and allowed to recover for 2 hours at 26°C. Following the 
2-hour recovery, the cell mixture was pelleted and resuspended in 100μl of LB to be plated on 
an LB plate containing Carb to select for transformants containing the plasmid (pMMB67EH). To 
confirm that the transformants contained the plasmid, a colony PCR was run on 8 colonies for 
each of ΔosmB, ΔompF, and ΔosmB ΔompF strains using the primers 
5’GTGTCGCTCAAGGCGCACTC3’ for the pMMB67EH backbone and 
5’GTCGTCGACTTAAGACCCACTTTCACATTTAAGT3’ for the tetR gene contained in the Tet 
reporter. The same protocol was followed for the transformation of the plasmid pACYC184 
containing a constitutive gfp into the PtetA::mCherry-containing ΔosmB, ΔompF, and ΔosmB 
ΔompF strains. After recovery from electroporation, the cells were plated on LB containing Carb 
and Cm to select for transformants containing both plasmids. Of the transformants, eight were 
screened for each of the three strains using the primer 
5’CACAGTTAAATTGCTAACGCAGTCAGGCAC3’ for the pACYC184 vector backbone and 
5’GTCGTCGACATGAGTAAAGGAGAAGAA3’ primer for the gfp insert .  





To confirm by PCR that the strains had up taken the plasmid and that the gene of 
interest was maintained in the plasmid, colony PCR was performed on eight colonies from each 
transformation (63). A colony PCR can be performed from a whole bacterial colony. To carry out 
the PCR, 2X OneTaq mastermix (MM) was used. First a master mix of the 10 µM primers, and 
OneTaq MM was made. All bacterial colonies were resuspended and lysed in 100μl of dH2O in 
sterile microcentrifuge tubes. 13.5µl of master mix was added to each test tube along with 
11.5µl of dissolved bacteria. The PCR was run with a 94°C initial denaturation followed by 30 
cycles of a 30s 94°C denaturation, a 30s annealing at 60°C, and 68°C extension for 90s.  
Following the 30 amplification cycles, there was a final extension for 5m at 68°C. The products 
were run out on a 1.5% agarose gel alongside a 2 log DNA ladder to confirm the expected DNA 
fragment was present and it was the correct size. 
Competitive Survival  
Overnight of a Y. pseudotuberculosis IP2666 containing a constitutive gfp in a pACYC184 
backbone (Cm resistant) and the ΔosmB strain (Cm sensitive) were grown separately in 2ml LB 
broth cultures at 26°C with rotation for 16-18 hours. The cultures were then diluted 1:100 
separately into fresh 2ml LB broth cultures and incubated for 2 hours at 26°C with rotation to re-
enter log phase of growth. After the 2-hour incubation, the strains were mixed in equal volumes 
and diluted 1:1,000 into 300μl of LB in 96-well plate and treated with 100ng/ml, 1μg/ml, 
4μg/ml, or left untreated. Single strain controls were also set up following the same process, 
using the same treatments. The 96-well plate with the cultures was then incubated for 4 hours 
at 37°C, with time points taken at 0 hours, 2 hours, and 4 hours to be plated on LB or LB Cm agar 
plates. At each time point 80μl of culture for each condition was removed and put on ice in a 
fresh 96-well plate. To obtain accurate CFU counts a serial dilution to a 10-3 dilution was 




performed on the sample. Following the serial dilution, three 10μl spots of each dilution for 
each treatment condition were plated for the mixed sample containing the ΔosmB strain and 
the gfp+ on both LB and LB CM agar plates. The ΔosmB single strain control was collected and 
diluted in the same manner and plated on LB, and the gfp+ Y. pseudotuberculosis was plated LB 
following the same plating and dilution method. All plates were grown for 2 days at 26°C before 
counting. Bacterial growth on LB plates depicts the total bacterial count, while colonies on 
LB/Cm are specifically the number of wild type (WT) cells within the cultures.  The number of 
mutant cells is calculated by subtracting the number of WT cells from the total.  After the 
colonies were counted, a competitive index (CI) was established for the mixed sample by 
subtracting the average colonies on the LB CM plates from the LB plates for each condition to 
establish the CFUs for the mutant. To establish a competitive index the formula (mutant/WT 
timepoint)/(mutant/WT inoculum) was used.   
Viability Assay 
To measure the single strain susceptibility of the ΔosmB compared to wild type IP2666 a 
single strain viability assay was performed to determine the number of cells that survived 
treatment with doxycycline. This was done by first growing broth cultures of ΔosmB and IP2666 
at 26°C for 16-18 h. These cultures were then diluted 1:100 into 2ml of LB broth and incubated 
for 2 hours at 26°C to reenter log phase. Following the 2-hour incubation the cultures were 
diluted 1:10,000 into fresh LB broth and treated with doxycycline at 100 ng/mL, 1 µg/mL, 4 
µg/mL or left untreated. The new cultures were then incubated at 37°C for 4 hours. Samples 
were taken at 0 hours, 2 hours, and 4 hours. To measure the number of viable bacteria in the 
sample the CUFs were counted by first diluting the sample to 10-3. Following the dilution three 
10μl spots of each dilution of each treatment condition was plated for each sample on LB plates. 
All plates were grown for 2 days before counting. 




In vivo Antibiotic Permeability  
To measure the effect of the mutations on the accumulation of doxycycline in vivo, 
overnight cultures of bacterial strains IP2666, ΔosmB, ΔompF, and ΔosmB ΔompF containing the 
tetracycline reporter and a constitutive gfp were used to infect five 6- to 8-week-old female 
C57BL/6 mice through tail vein injections. Overnights of each strain were grown in 2ml of 2xyT 
broth at 26°C for 16 to 18 hours with rotation in plastic test tubes. The cultures were then 
diluted 1:10,000 into filter sterilized sterile PBS to prepare an inoculum with roughly 1x103 CFU 
of Y. pseudotuberculosis in 100µl. To perform tail vein injections, mice were warmed under a 
heat lamp to cause the vein to dilate until they showed signs of being warm, such as washing 
their face and slowed movement. Once the mice were sufficiently warmed, a mouse is taken 
from the cage and placed in a brass restrainer. Once the mouse was restrained the tail was 
sprayed with 70% ethanol to both ensure the injection was not introducing bacteria from the 
tail into the blood and to cause the vein to come closer to the surface. The vein was injected 
with 100μl of the inoculum and placed in a clean cage. Following the infection, the inoculum is 
serial diluted to 10-3 and three 10μl drops were plated for each dilution to confirm the 103 
CFU/100µl dose of the inoculum. The mice were treated with 100μl of 7.2mg/ml of doxycycline 
48 hours after infection via intraperitoneal injection. 24 hours following the treatment the 
spleens of the mice were harvested. Half of each spleen was homogenized, serial diluted to 10-3, 
and plated to determine CFUs per spleen. The other half of the spleen was fixed in 4% PFA in 
PBS overnight at 4°C, frozen-embedded in OCT, and stored at -80°C to be sectioned and imaged. 
Staining and Imaging of Embedded Spleens 
Spleens embedded in OCT were sectioned into 10μm sections. The sections on slides 
were thawed in PBS for 20 m, then stained with 100μl of a 1:10,000 dilution of Hoechst. The 
stained sections were then washed for 2 m in PBS 3 times and mounted with Prolong Gold 




antifade mounting media and a glass coverslip. The mounted slides were allowed to cure 
overnight in a drawer to prevent bleaching. Sections were scanned at 200x magnification to 
identify any microcolonies, images of microcolonies were then captured at 630x using three 
fluorescent filters DAPI (excitation 358nm, emission 460nm), eGFP (excitation 488 nm, emission 
510 nm), and mCherry (excitation 580nm, emission 610nm). Imaging was done using an 
apotome to deconvolute background in the images.  This process was repeated for all 
microcolonies in all the collected tissues.  
In vitro Antibiotic Diffusion  
To test the effects of the genes of interest on antibiotic accumulation in bacterial cells in 
vitro 2ml LB broth cultures of IP2666, ΔosmB, ΔompF, and ΔosmB ΔompF, all containing the 
tetracycline reporter and constitutive gfp, were grow for 16 to 18 hours with rotation. The 
cultures were then diluted 1:100 and treated with doxycycline at 10ng/ml, 100ng/ml, and 
1μg/ml or left untreated. The diluted cultures were incubated at 37°C for 4 hours with rotation. 
At 4 hours, 200μl of each culture was removed and used to detect absorbance (OD 600nm) to 
measure growth or density and to detect relative reporter expression by detecting mCherry 
emission at 610nm using a 560nm excitation to measure total in a plate reader. This same 200μl 
sample was pelleted at 15,000rpm in sterile microcentrifuge tubes and resuspended in 200μl of 
4% PFA and fixed overnight at 4°C to be used for imaging to measure single cell fluorescence 
intensity.  
Imaging in vitro Antibiotic Diffusion 
To image the fixed bacterial cells, cells were immobilized onto slides using agarose pads. 
To make agarose pads, 1% agarose in PBS was put on a slide, covered with a square coverslip, 
and left to cool for 20 m. The cover slip was removed and 10μl of the fixed bacterial cells were 
pipetted onto the agarose pad and covered with a fresh coverslip. The bacterial cells in 4% PFA 




were pelleted at 15,000rpm, the PFA was removed, and the cells were resuspended in 50μl of 
PBS. 4μl of the resuspension was then added onto the agarose pad. The cells on the agarose 
pads were then imaged at 630x magnification and images were captured using DIC and 
fluorescence microscopy for GFP and mCherry at the previously mentioned excitation and 
emission with exposures of 120ms and 13ms for the respective channels. Around 5 images were 
taken for each sample depending on the density of cells present on the agarose pad, the higher 
concentrations of antibiotics have fewer cells per frame and required more images to capture 
between 20 and 50 bacterial cells per frame.  
Image Analysis 
Images taken from the agarose pads were exported as .ZVI files to be uploaded to 
Volocity (manufacturer, city). To identify bacteria in each image in each channel find objects was 
used to identify objects. The lower size limit of objects was set at 1μm and the upper size limit at 
2μm. Objects touching the edge were excluded and “separate objects” was run to identify 
bacteria more accurately if they were clustered together with a lower size limit of 1μm. After 
the images were analyzed the mean mCherry signal of each object identified was divided by the 
mean gfp signal to control for translational levels in each bacterium. These data were then 
imported into Prism (manufacturer, city) to graph and analyze. The data was analyzed using 
Kruskal-Wallis ANOVA with a Dunn’s multiple comparison to determine significance. 
Site-Directed Mutagenesis  
To produce the M3 and M6 mutation in the tetracycline operator site (tetO) of 
PtetA::mCherry-directed mutagenesis was attempted using the primer sets 
5’CCACTCCCTAACAGTGTTAGAGAAAAG3’ and 5’CTTTTCTCTAACACTGTTAGGGAGTGG3’ for the 
M3 mutant, and 5’TTACCACTCCGTATCAGTGATACAGAAAAGTGA3’ and 
5’TCACTTTTCTGTATCACTGATACGGAGTGGTAA3’ for the M6 mutant. The polymerase PfuUltra II 




(Agilent Technologies, La Jolla, CA) was used to incorporate these mutations into a 
PtetA::mCherry construct in a pMMB67EH plasmid. The following PCR cycling parameters were 
used: one cycle 92°C, 2 m 30 cycles of 92°C for 10s, 60°C for 20s, 68°C for 5m; and one cycle of 
68°C 5 m followed by a 4°C infinite hold. After initial attempts at site directed mutagenesis were 
unsuccessful another attempt was made with new primer sets to incorporate the M3 and M6 
mutations into both tetO sequences. The primer set 
5’ATTTTTGACACTCTAACATTGTTAGAGTTATTTTACCACTCCCTAACAGTGTTAGAGAAAAG3’ and 
5’TTCACTTTTCTCTAACACTGTTAGGGAGTGGTAAAATAACTCTAACAATGTTAGAGTGTC3’ was used 
for the M3 mutation, and the primer set 
5’TTTGTTGACACTGTATCATTGATACAGTTATTTTACCACTCCGTATCAGTGATACAGAAAAGTGA3’ and 
5’ATTTCACTTTTCTGTATCACTGATACGGAGTGGTAAAATAACTGTATCAATGATACAGTGTCAACA3’ 
was used to incorporate the M6 mutation. This was done following the same PCR cycling 
settings as above. 





Exposure to Doxycycline Increases the Expression of osmB and ompF. 
When treated with 100ng/ml of doxycycline for 2 hours, Y. pseudotuberculosis 
differentially expressed 4 genes with at least a 2-fold change and a significant P-value (Figure 4. 
A). The two upregulated genes were ompF and osmB, and the two downregulated genes were 
tusB, and CNFy (Figure 4. B). We hypothesized that these genes play a role in the development 
of tolerant subpopulations capable of surviving treatment with higher doses of doxycycline. 
Based on the location of the OsmB and OmpF in the outer membrane we hypothesized that 
these proteins could be affecting antibiotic accumulation and reducing the antibiotic 
susceptibility of Y. pseudotuberculosis.  This thesis focuses specifically on the two upregulated 
genes, ompF and osmB. To determine if increased expression of ompF and osmB plays a role in 
the survival of Y. pseudotuberculosis during antibiotic treatment, deletion strains with each of 
the individual gene deleted, and a strain with both genes deleted, were constructed.  
Effect of OsmB and OmpF on Antibiotic Accumulation in vitro 
We hypothesized that the outer membrane associated proteins OsmB and OmpF, which 
are induced by exposure of exposure to 100ng/ml of doxycycline could affect tolerance to 
antibiotics by altering the permeability of the bacterial cell to doxycycline.  If these genes alter 
the amount of doxycycline that is able to accumulate within an individual cell, the cell may be 
able to survive treatment.  To determine if OsmB and OmpF altered antibiotic accumulation 
reporter strains with a tetracycline, inducible mCherry and a constitutive gfp (gfp+) were 
constructed for the ΔosmB, ΔompF, and ΔosmB ΔompF strains. The tetracycline reporter 
introduced into these strains was constructed by fusing the tetA promotor along with the 
repressor tetR from the tetracycline resistance transposon tn10 to the fluorescent protein  





Figure 4.  Transcriptional adaptation of Y. pseudotuberculosis during exposure to 100ng/ml of doxycycline. 
IP2666 was incubated with 100ng/ml of doxycycline for 2h RNA was isolated and processed through RNA-seq. 
Transcript levels were compared to an untreated control to identify genes with an at least 2-fold change and a 
statistically significant change in transcript level. A) A volcano plot of the change in transcript levels in the treated 
population of Y. pseudotuberculosis. B) Altered genes with gene descriptions and transcript values for the treated and 
untreated samples as well as fold change and adjusted p-value. The genes that met the criteria for significant changes 
in expression and a 2-fold change are highlighted in red. 




mCherry (Figure 5. A). In this system the repressor remains bound to the operator tetO tin the 
absence of antibiotics. When antibiotics are added to this system TetR becomes unbound to 
tetO which leads to the transcription of mCherry.  This reporter allows for the approximation 
antibiotic accumulation within a cell.  The constitutive gfp is included as a control in these 
strains to approximate translational activity. More metabolically active cells may be producing 
more mCherry in response to similar amounts of antibiotic. Measuring gfp production can help 
account for different metabolic rates that occur in bacterial populations and provide a more 
accurate measurement of antibiotic diffusion. The ΔosmB, ΔompF, and ΔosmB ΔompF reporter 
strains were incubated with 10ng/ml, 100ng/ml, and 1 μg/ml of doxycycline to measure the 
accumulation of antibiotic in each strain. Fluorescence was measured on a plate reader 
indicated that there was no difference at the population level in vitro (Figure 5. B-E). The 
mCherry fluorescence measured on the plate reader was normalized to the optical density of 
the culture to approximate the single cell fluorescence. The plate reader measures an average 
fluorescence of the entire population and measuring the population level fluorescence may not 
adequately represent what is occurring the single cell level. 
The samples were also imaged at the single bacterial cell level to measure differences in 
mCherry expression. In these images mCherry signal was compared to GFP signal to ensure that 
mCherry signal was an accurate measurement of doxycycline exposure. This provides a relative 
mCherry signal to GFP signal.  Analysis of the single cell image indicated that there was a 
significant increase in antibiotic accumulation in the ΔompF strain at all concentrations of 
antibiotics with a dramatic increase to 10μg/ml. At 10ng/ml, ΔosmB did not have significantly 
different accumulation of antibiotics. Surprisingly, the ΔosmB ΔompF had more antibiotic 
accumulation than the wild type, but significantly less accumulation than the ΔompF strain  




Figure 5. Population level antibiotic accumulation during treatment with clinically relevant doses of doxycycline. 
(A) Diagram of the reporter used to measure antibiotic accumulation based on the Tre of the tetracycline resistance 
gene in the Tn10 transposon. (B-E) Fluorescence from the PtetA::mCherry reporter without treatment and with 
10ng/ml, 100ng/ml, and 1μg/ml doses of doxycycline in the indicated Y. pseudotuberculosis strains after treatment 
for 4h at 37°C. Fluorescence detected by a plate reader. Fluorescent signal from mCherry was normalized to the 
optical density of the culture at 600nm to normalize for growth of the bacteria. The mean of three biological 
replicates are shown with the standard deviation. Kruskal-Wallis with uncorrected Dunn’s was used to determine 
significance ns, not significant. 
  
 




(Figure 6. B). This indicates that there may be some interaction between the two proteins. At 
100ng/ml of doxycycline the ΔompF strain has a lower relative mCherry value than the wild 
type. This is likely due to greater accumulation of doxycycline preventing the translation of 
mCherry in the ΔompF strain. ΔosmB showed no difference at 100ng/ml. The slightly decreased 
relative mCherry expression in the ΔosmB ΔompF strain at 100ng/ml also is likely due to greater 
doxycycline accumulation (Figure 6. C). At 1μg/ml all three strains had significantly higher 
accumulation of doxycycline than the wild type (Figure 6. D). These results indicate that there is 
an effect of OsmB and OmpF on doxycycline accumulation in Y. pseudotuberculosis. OmpF may 
play a more important role at lower doses of doxycycline and the increased accumulation of 
antibiotics in the ΔompF was mitigated by the deletion of osmB, which may indicate that there is 
a relationship between the two proteins. 
Role of OsmB in Survival of Y. pseudotuberculosis during Doxycycline Treatment in 
Phosphate Buffered Saline 
To determine if OsmB contributes to survival during treatment with doxycycline, the 
survival of ΔosmB was to compare to the survival of IP2666 during exposure to doxycycline in 
vitro. A gfp+ wild type IP2666 strain and the ΔosmB knock out strain were used to test this 
possibility. Both strains were grown in the same culture during exposure to doxycycline to 
ensure that they were exposed to the same conditions and any differences in survival could be 
attributed to the absence of OsmB.  The gfp+ wild type strain was used because it contains a 
chloramphenicol-resistance cassette, which means that when grown in the same culture as the 
ΔosmB the wild type cells could be selected for by plating on chloramphenicol-containing media 
to measure growth of each strain. Both strains were grown Phosphate Buffered Saline (PBS) to 
determine the competitive survival. The mixed cultures were treated with 10ng/ml, 100ng/ml,  





Figure 6. At the single cell level OmpF and OsmB have a significant impact on antibiotic accumulation. 
(A-D) Quantification of mCherry signal from the PtetA::mCherry reporter relative to GFP signal in single Y. 
pseudotuberculosis cells in untreated cells and at 10ng/ml, 100ng/ml, and 1μg/ml doses of doxycycline in the 
indicated strains after treatment for 4h at 37°C. Each dot represents an individual cell. The mean and standard 
deviation are indicated in red bars. Kruskal-Wallis with uncorrected Dunn’s was used to determine significance.  
*, P < 0.05, ****, P < 0.0001 ns, not significant. 




and 1μg/m of doxycycline. These doses of doxycycline were used based on their previous 
identification as concentrations experienced by Y. pseudotuberculosis in microcolonies during 
treatment in the mouse model of infection (73). PBS was used to prevent growth during the 
experiment, and control for growth difference between the two strains, in an attempt to only 
measure antibiotic-mediated killing. We hypothesized that deletion of osmB would lead to less 
survival in the presence of antibiotics. A competitive index was used to determine if there was a 
survival advantage for the wild type. This was calculated by comparing the ratio of ΔosmB to 
IP2666 at 2 hours to the initial ratio of ΔosmB to IP2666 (mutant/WT timepoint)/(mutant/WT 
inoculum).  The competitive indexes showed no significant difference at any concentration, 
indicating that the disruption of osmB had no impact on antibiotic tolerance in this system 
(Figure 7. A).  
 To understand why this may be the case, the total colony forming units (CFU) in the 
inoculum and at the 2-hour time point was counted. The difference between the inoculum and 
the 2-hour time point was used to determine if there was growth (ΔCFU). Without doxycycline 
IP2666 is capable of doubling once in PBS. When treated with doxycycline up to a concentration 
10μg/ml IP2666 also was able to double (Figure 7. C).  This indicated that growth in PBS for 2 
hours was enough to induce a persistent phenotype in this strain.  The ΔosmB strain also 
showed no significant susceptibility to doxycycline at all concentrations used (Figure 7. B).  This 
made it difficult to determine whether there was any survival advantage for either strain and led 
to the redesign of the experiment. It is interesting to note that only 2 hours in a minimal media 
can induce such a robust persistence in Y. pseudotuberculosis IP2666.  





Figure 7. PBS induces tolerance to doxycycline in Y.  pseudotuberculosis. PBS cannot be used to measure survival. 
(A) Competitive survival of ΔosmB and IP2666 after 2h of treatment with the indicated doses of doxycycline at 
37°C in PBS. A competitive index was generated for each treatment condition to determine if there was a survival 
advantage in the WT strain. Each dot represents an individual replicate. The mean and standard error of the 
replicates is represented with red bars. (B) Average change in colony forming units (ΔCFU) in the ΔosmB strain at 
indicated concentrations of doxycycline after 2 hours of treatment with doxycycline in PBS at 37°C. The ΔCFU was 
calculated by determining the difference in CFUs at time 0 and 2h. The symbols represent the mean of 3 replicates 
the red bars indicate standard error. (C) Average ΔCFU in the IP2666 strain at indicated concentrations of 
doxycycline after 2 hours of treatment with doxycycline in PBS at 37°C. The ΔCFU was calculated by determining 
the difference in CFUs at time 0 and 2h. The symbols represent the mean of 3 replicates the red bars indicate 
standard error. Kruskal-Wallis with uncorrected Dunn’s was used to determine significance. ns, not significant 
  




Role of OsmB in Survival of Y. pseudotuberculosis during Doxycycline Treatment in LB 
After initial experiments in PBS, the media was switched to standard bacteriological 
media (LB broth) to measure the effect of osmB more accurately on antibiotic susceptibility 
without inducing tolerance through growth in PBS. The concentrations of antibiotics used were 
also altered to focus on physiologically relevant doses of doxycycline experienced by Y. 
pseudotuberculosis in the mouse model and an inhibitory 4μg/ml dose of doxycycline. In this 
revised system, we would expect to see more antibiotic susceptibility and death in the ΔosmB 
strain if osmB plays a protective role against doxycycline in Y. pseudotuberculosis. Again, both 
the gfp+ IP2666 strain and ΔosmB were incubated together in the presence of either 100ng/ml, 
1μg/ml, or 4μg/ml of doxycycline and plated to measure the relative survival of each strain 
(Figure 8. A-D). The relative survival during doxycycline treatment was again determined by 
calculating a competitive index. The competitive indexes indicated that osmB does not affect 
antibiotic tolerance at 100ng/ml, 1μg/ml, of 4μg/ml. There is a great degree of variability at 4 
hours in the observed competitive indexes in the 4μg/ml and 1μg/ml treatment conditions. This 
may be due to greater inhibition or killing reducing the sample size and leading to greater 
variability. There was not a significant difference in the competitive index of either strain with 
any of the concentrations of antibiotics used at 2 hours or 4 hours. This was unexpected as the 
gene was upregulated in response to 100ng/ml of doxycycline at 2 hours and there was 
increased doxycycline accumulation at 1μg/ml. The increased accumulation in the ΔosmB strain 
may not have been significant enough to inhibit bacterial growth. 
  







Figure 8. OsmB does not affect antibiotic susceptibility of Y. pseudotuberculosis to 
doxycycline at clinically relevant doses. (A) Untreated sample used to determine competitive index for 
treatment groups. All values are 1 for all replicates because competitive indexes are calculated by taking the ratio 
of the ratio of wild type to mutant in the treated to untreated. Both numbers are the same in the untreated 
condition, so all values are 1. (B-D) The competitive index of ΔosmB to IP2666 at the indicated concentrations of 
doxycycline. Cultures were incubated at 37°C with doxycycline for 4 hours with a sample removed and plated at 
0h, 2h, and at the final 4h timepoint. Each dot represents a replicate, red bars indicate mean and standard error. 
Kruskal-Wallis with uncorrected Dunn’s was used to determine significance. ns, not significant 
   




Role of OsmB and OmpF in Survival of Y. pseudotuberculosis during Doxycycline 
Treatment in vivo 
To determine if these genes had an effect on antibiotic susceptibility in vivo that could not be 
seen in vitro, a mouse model of infection was used. To set up for the mouse infection four 
strains to be used in the infection were grown overnight. The strains used were the ΔosmB, 
ΔompF, and ΔosmB ΔompF tetracycline reporter strains, and an IP2666 tetracycline reporter 
strain that had been used to determine antibiotic accumulation in vitro. Before the infection, the 
overnights were diluted to an estimated 1x103 CFU/ml in the inoculum. Each strain was used to 
infect a different set of five mice through the tail veins.  The mice were then treated with 
doxycycline 48 hours after infection to allow for Y. pseudotuberculosis to establish an infection 
in the spleen and form microcolonies. Delaying treatment also more accurately replicates a 
clinical setting where infected individuals would likely only seek treatment after the onset of 
symptoms. 24 hours after treatment with doxycycline the mice were sacrificed, and their 
spleens were harvested. Half of each spleen was homogenized and plated to approximate total 
colony forming units of Y. pseudotuberculosis in each spleen. This measurement provides insight 
into doxycycline’s effectiveness at clearing Y. pseudotuberculosis infections for each strain. The 
other half of each spleen was embedded in OCT for sectioning and imaging to measure 
antibiotic accumulation within the microcolonies. The CUFs per spleen of the treated mice 
indicated that there was no significant increase in antibiotic susceptibility of the mutant strains 
(Figure 9.). This may be due to mouse-to-mouse variability and will need to be confirmed in a 
competition experiment where mice are infected with both a mutant and a wild type strain to 
accurately measure whether there is an effect of OmpF or OsmB on antibiotics susceptibility in 
vivo.  
  





Figure 9.  Single strain infections do not indicate a survival difference between ΔosmB, ΔompF, and ΔosmB 
ΔompF and WT IP2666 when treated with doxycycline. 
Six- to eight-week-old C57BL/6 mice were infected with roughly 103 CFU/ml of each of the indicated Y. 
pseudotuberculosis strains. Mice were treated 48h after the infection with doxycycline, and spleens were 
harvested 24 hours after treatment to measure CFU/spleen. Each dot represents an individual mouse. This data 
represents CFUs quantifications from 3 individual experiments. The red bars indicate mean and standard error. 
Kruskal-Wallis with uncorrected Dunn’s was used to determine significance. ns, not significant 
 
  





 Antibiotic persistence remains a major concern in both treating infection and the 
continued emergence of antibiotic resistance. Establishing targets within persister or tolerant 
bacterial populations may allow for future development of drugs to specifically target these 
populations. This strategy could potentially promote the complete clearance of infections and 
prevent recurrent infections.   
RNA-seq of Y. pseudotuberculosis exposed to physiologically relevant doses of 
doxycycline led to the Identification of four differentially expressed genes: osmB, ompF, tusB 
and CNFy. Further characterization of these genes to identify the role they play in persistence 
was carried out to determine if differential gene expression led to protection and ineffective 
clearance by doxycycline in our mouse model. The results of these experiments surprisingly 
indicated that while OmpF and OsmB have a significant impact on accumulation of antibiotics at 
subinhibitory and inhibitory concentrations, OsmB does not seem to contribute to survival when 
treated with doxycycline.   
The significant impact of OmpF on antibiotic accumulation in this system is a unique 
finding, as it is generally thought that porins allow for influx of antibiotics. The increase in 
intracellular accumulation of doxycycline at physiologically relevant doses of doxycycline in the 
ΔompF strain indicated that the presence OmpF is lowered antibiotic concentration within the 
cell. This result indicated that at the concentrations of doxycycline experienced in Y. 
pseudotuberculosis microcolonies during treatment, this porin is played a more important role 
in the passive diffusion of doxycycline out of the cell. The effects mediated by OmpF can only be 
accomplished through passive diffusion because it is not an efflux pump. OmpF expression may 
be beneficial at lower concentrations of doxycycline or when there is transient exposure to 
antibiotics. In these situations, the extracellular antibiotic concentration may decrease to a 




lower concentration than the intracellular concentrations of antibiotics before the antibiotic is 
able to kill the cell. The concentration gradient could then drive diffusion of the antibiotic out of 
the cell through OmpF. 
Other data collected in the lab indicated that there is no survival difference in the 
ΔompF strain when treated with doxycycline. This is surprising based on the significant role that 
OmpF played in antibiotic accumulation at 10ng/ml and 100ng/ml of doxycycline. The lack of a 
survival difference, along with a difference in the antibiotic accumulation, suggests that the 
expression of OmpF may be beneficial during interaction with antibiotics for less than 2 hours. 
To determine if this is the case, additional experiments assessing potential for growth following 
shorter exposures to doxycycline could be performed. The OmpF deficient mutant may not be 
able to replicate as efficiently following treatment if doxycycline cannot exit the cell. Short-term 
protection may be relevant in the host where antibiotic concentrations wain after treatment 
and may allow for survival during transient exposure to lethal doses doxycycline. 
Attempting to block OmpF as a potential drug target may not work however, because 
porins have previously been shown to be very important in the influx of antibiotics. This is the 
first demonstration of their role in the efflux of antibiotics. Porin-deficient mutants have shown 
increased antibiotic persistence in E. coli (83).  The balance between targeting persistent cells 
and inducing persistence is a challenge, in that many proposed methods of clearing persistent 
infections, such as the use of ROS, are often stressors that lead to persistence. 
Despite the observed increase in osmB expression in response to doxycycline there was 
little effect on antibiotic accumulation or susceptibility in when the gene was deleted. The 
ΔosmB strain showed no accumulation difference at 10ng/ml or 100ng/ml of doxycycline.  
However, there was slightly increased accumulation at 1μg/ml in the ΔosmB strain. This 




indicated that while OsmB expression is induced at 100ng/ml of doxycycline, it only affects 
accumulation at higher lethal concentrations doxycycline. The slight mitigation of accumulation 
at inhibitory concentrations of doxycycline did not seem to be enough to greatly impact the 
survival of Y. pseudotuberculosis. 
While there was an increased accumulation of antibiotics in the double mutant at 
10ng/ml, the larger effect of OmpF seemed to be mitigated by the deletion of OsmB. This is a 
rather interesting result implying that there may be some interaction between these two 
proteins. Deletion of osmB may have rescued the ΔompF phenotype by inducing the expression 
of another porin such as, OmpC, but further experiments are required to assess what is 
occurring with this mutant and the relationship between the two proteins. OmpC and OmpF are 
part of a family of outer membrane proteins that allow for diffusion through the outer 
membrane of gram-negative bacteria. OmpC is another major porin that is that is regulated by 
osmolarity as with OmpF. OmpC-deficient E. coli mutants have been shown to be highly tolerant 
to antibiotics. This indicates that antibiotics diffuse into the cells through this porin, suggesting 
that increased expression of this porin may also facilitate outward diffusion of antibiotics and 
lead to the rescued phenotype in the ΔosmB ΔompF mutant. This expression could be due to 
altered osmolarity in the cell because of the lack of OsmB on the outer membrane. Future work 
could focus on understanding this interaction as not much is known about the role of OsmB. 
Many lipoproteins are transduced across the outer membrane of Gram-negative bacteria 
through other porins in the Omp family. OmpF and OsmB may have a similar relationship; 
however, OmpF has not been shown to take part in this type of interaction.   
It is not known if ompF and osmB are being upregulated in the same population of 
bacteria. The initial RNA-seq screen identified population-level gene expression patterns in 
response to doxycycline exposure. RNA-seq does not; however, measure transcriptional changes 




at a single-cell level.  The lack of single-cell data allows for the possibility that specific 
subpopulations could express these genes.  Based on the results for the in vitro accumulation 
experiments, I would expect that these genes may be expressed by the same population at 
1μg/ml of doxycycline. At this concentration both genes affect accumulation of doxycycline. At 
lower concentrations, between 10ng/ml and 100ng/ml, there may be two specific populations 
with different expression profiles for these genes; one population that only expresses OmpF and 
one with OsmB and OmpF expression. To understand the expression patterns within the 
population it will be beneficial to perform reporter experiments with OsmB and OmpF reporters 
both in vivo and in vitro.  These strains could then be used in in vitro antibiotic exposure 
experiments to determine if the genes are expressed in the same population of cells. They could 
also be used in the mouse infection model to identify if there are subpopulations within 
microcolonies that differentially express these genes in response to antibiotics.  
The rapid induction of antibiotic tolerance in the minimal media PBS was both an 
unexpected and highly interesting result. Within 2 hours, the nutrient deprived bacteria became 
tolerant to significantly higher doses of doxycycline than Y. pseudotuberculosis grown in LB. This 
rapid shift to an almost completely tolerant phenotype would be interesting to explore further. 
It is likely due to a shutdown of central metabolism in response to starvation, however Y. 
pseudotuberculosis can often undergo one division event after being moved into PBS. These 
pathways are likely similar to those utilized by other bacteria to enter a dormant state, but 
further elucidating these pathways in a Y. pseudotuberculosis model may present unique 
pathways or targets to understand the development of persistence. Performing similar RNA-seq-
based experiments to determine which sets of genes are being expressed in response to 
starvation could potentially inform further experiments, including the design of new reporters, 
to identify bacteria that have shifted into a dormant state in an infection model within a 




microcolony. If a screen identifies genes that are altered in the population of bacteria that 
survive treatment with doxycycline in when grown in PBS, the promotor of those genes could be 
fused to a fluorescent protein to generate a reporter. These reporters could be used to identify 
bacteria that are undergoing the same response that leads to persistence in PBS in the mouse 
model within a microcolony. 
In vivo antibiotic susceptibility of Y. pseudotuberculosis WT IP2666, ΔosmB, ΔompF, and 
ΔosmB ΔompF in single strain infections was not significantly different 24 hours after treatment. 
The experiment was designed to determine if there was differential antibiotic accumulation in 
vivo and lacks data for the bacterial load at 48-hour post-infection time point when treatment 
was administered.  This made it difficult to determine if the similar CFUs observed after 
treatment are the result of the same amount bacterial death from antibiotic treatment. The 
strains may have had growth differences in the host and replicate to higher levels before 
treatment with doxycycline. The unknown bacterial load before treatment makes it difficult to 
determine if there are significant differences in bacterial clearance when treated with 
doxycycline. Unpublished data from the lab suggests that the ΔosmB strain outperforms IP2666 
in a mouse infection, so it is possible that the knockout strains significantly outgrew IP2666 prior 
to treatment and were then killed more efficiently. Based on mouse-to-mouse variability, these 
experiments should be repeated for all strains in a competition model where a mutant and wild 
type strain are used to infect the same mouse. This type of experiment could determine if there 
is increased susceptibility of the mutants to antibiotics in vivo and allow for a comparison in the 
same tissues. Using the same tissues reduces some variability because both strains are 
experiencing the same dose of antibiotics and are encountering the same immune response in 
the mouse. This is possible because the microcolonies established by Y. pseudotuberculosis are 
clonal and each would represent either the wild type or a mutant strain. The clonal colonies 




allow for the comparison of two strains side by side in the same tissue. Persistence is generally 
thought of as a phenotype that protects the bacteria from multiple drugs so it would also be 
beneficial to study these genes in the context of other classes of antibiotics to determine if the 
accumulation differences are maintained across a broad range of antibiotics, or if it is specific to 
doxycycline.  
Overall, the data in this thesis indicate that OmpF and OsmB significantly reduce 
doxycycline accumulation within Y. pseudotuberculosis. However, the reduced accumulation 
does not aid in the survival of Y. pseudotuberculosis when treated with clinically relevant doses 
of doxycycline. The identification of increased accumulation of antibiotic in the OmpF porin-
deficient mutant has not previously been reported. The role of OmpF in diffusion of doxycycline 
out of a cell is unique and presents another possible mechanism of tolerance in bacterial species 
that lack multidrug efflux pumps. OsmB has not previously been associated with antibiotic 
persistence or pathogenicity. While the impacts on accumulation of antibiotics were not large 
and there was no effect on Y. pseudotuberculosis survival in the presence of doxycycline, 
insights into any potential role of OsmB are significant in that there is a very limited body of 
work involving this protein. The mitigation of increased antibiotic accumulation in the OmpF-
deficient mutant caused by deleting osmB indicates that there may be some interaction 
between these two proteins that has not previously been reported.  
In conclusion, the findings in this work to identify potential targets for the treatment of 
antibiotic persisters indicate that OmpF and OsmB affect antibiotic accumulation in Y. 
pseudotuberculosis. The results are clear, however, that OsmB does not affect antibiotic 
susceptibility at clinically relevant dose of doxycycline and targeting OsmB does not appear to 
be a viable method for the treatment of persister bacteria within an infection. 
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